Department of Surgical Oncology, National Taiwan University Cancer Center.
Department of Surgery, Division of Colorectal Surgery, National Taiwan University Hospital, Hsin-Chu Branch, Hsinchu, Taiwan, Republic of China.
Int J Surg. 2024 Apr 1;110(4):2034-2043. doi: 10.1097/JS9.0000000000001061.
BACKGROUND: The territory of D3-D4 lymphadenectomy for upper rectal and sigmoid colon cancer varies, and its oncological efficacy is unclear. This prospective study aimed to standardize the surgical technique of robotic D3-D4 lymphadenectomy and clarify its oncologic significance. METHODS: Patients with upper rectal or sigmoid colon cancer with clinically suspected more than N2 lymph node metastasis were prospectively recruited to undergo standardized robotic D3-D4 lymphadenectomy. Immediately postsurgery, the retrieved lymph nodes were mapped to five N3-N4 nodal stations: the inferior mesenteric artery, para-aorta, inferior vena cava, infra-renal vein, and common iliac vessels. Patients were stratified according to their nodal metastasis status to compare their clinicopathological data and overall survival. Univariate and multivariate analyses were performed to determine the relative prognostic significance of the five specific nodal stations. Surgical outcomes and functional recovery of the patients were assessed using the appropriate variables. RESULTS: A total of 104 patients who successfully completed the treatment protocol were assessed. The standardized D3-D4 lymph node dissection harvested sufficient lymph nodes (34.4±7.2) for a precise pathologic staging. Based on histopathological analysis, 28 patients were included in the N3-N4 nodal metastasis-negative group and 33, 34, and nine patients in the single-station, double-station, and triple-station nodal metastasis-positive groups, respectively. Survival analysis indicated no significant difference between the single-station nodal metastasis-positive and N3-N4 nodal metastasis-negative groups in the estimated 5-year survival rate [53.6% (95% CI: 0.3353-0.7000) vs. 71.18% (95% CI: 0.4863-0.8518), P=0.563], whereas patients with double-station or triple-station nodal metastatic disease had poor 5-year survival rates (24.76 and 22.22%), which were comparable to those of AJCC/UICC stage IV disease than those with single-station metastasis-positive disease. Univariate analysis showed that the metastatic status of the five nodal stations was comparable in predicting the overall survival; in contrast, multivariate analysis indicated that common iliac vessels and infra-renal vein were the only two statistically significant predictors (P<0.05) for overall survival. CONCLUSIONS: Using a robotic approach, D3-D4 lymph node dissection could be safely performed in a standardized manner to remove the relevant N3-N4 lymphatic basin en bloc, thereby providing significant survival benefits and precise pathological staging for patients. This study encourages further international prospective clinical trials to provide more solid evidence that would facilitate the optimization of surgery and revision of the current treatment guidelines for such a clinical conundrum.
背景:对于高位直肠和乙状结肠癌的 D3-D4 淋巴结清扫术的范围存在差异,其肿瘤学疗效尚不清楚。本前瞻性研究旨在规范机器人 D3-D4 淋巴结清扫术的手术技术,并阐明其肿瘤学意义。
方法:前瞻性招募临床疑似 N2 以上淋巴结转移的高位直肠或乙状结肠癌患者,接受标准化的机器人 D3-D4 淋巴结清扫术。术后立即对切除的淋巴结进行映射,分为五个 N3-N4 淋巴结站:肠系膜下动脉、腹主动脉旁、下腔静脉、肾下静脉和髂总血管。根据患者的淋巴结转移状态进行分层,比较其临床病理数据和总生存率。使用单变量和多变量分析确定五个特定淋巴结站的相对预后意义。使用适当的变量评估患者的手术结果和功能恢复情况。
结果:共有 104 例成功完成治疗方案的患者进行了评估。标准化的 D3-D4 淋巴结清扫术可采集足够的淋巴结(34.4±7.2)进行准确的病理分期。根据组织病理学分析,28 例患者归入 N3-N4 淋巴结转移阴性组,33、34 和 9 例患者归入单站、双站和三站淋巴结转移阳性组。生存分析显示,单站淋巴结转移阳性组和 N3-N4 淋巴结转移阴性组的估计 5 年生存率无显著差异[53.6%(95%CI:0.3353-0.7000)与 71.18%(95%CI:0.4863-0.8518),P=0.563],而双站或三站淋巴结转移疾病患者的 5 年生存率较差(24.76%和 22.22%),与单站淋巴结转移阳性疾病患者的 AJCC/UICC 分期 IV 期疾病相似。单变量分析显示,五个淋巴结站的转移状态在预测总生存率方面具有可比性;相比之下,多变量分析表明,髂总血管和肾下静脉是唯一两个具有统计学意义的总生存率预测因子(P<0.05)。
结论:使用机器人方法,可以安全地以标准化方式进行 D3-D4 淋巴结清扫术,整块切除相关的 N3-N4 淋巴区域,从而为患者提供显著的生存获益和准确的病理分期。本研究鼓励进一步开展国际前瞻性临床试验,提供更可靠的证据,以优化手术,并修订当前治疗指南,解决这一临床难题。
ORL J Otorhinolaryngol Relat Spec. 2024
Cochrane Database Syst Rev. 2025-6-10
Cochrane Database Syst Rev. 2017-10-2
Dis Colon Rectum. 2024-10-1
Cochrane Database Syst Rev. 2014-11-13
Cochrane Database Syst Rev. 2013-3-28
Cochrane Database Syst Rev. 2015-9-21
Cochrane Database Syst Rev. 2011-4-13
Gastroenterol Rep (Oxf). 2021-9-23
World J Surg Oncol. 2020-8-28